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Aim: The nationwide Danish Testicular Cancer database consists of a retrospective research 
database (DaTeCa database) and a prospective clinical database (Danish Multidisciplinary 
Cancer Group [DMCG] DaTeCa database). The aim is to improve the quality of care for patients 
with testicular cancer (TC) in Denmark, that is, by identifying risk factors for relapse, toxicity 
related to treatment, and focusing on late effects.
Study population: All Danish male patients with a histologically verified germ cell cancer 
diagnosis in the Danish Pathology Registry are included in the DaTeCa databases. Data collec-
tion has been performed from 1984 to 2007 and from 2013 onward, respectively.
Main variables and descriptive data: The retrospective DaTeCa database contains detailed 
information with more than 300 variables related to histology, stage, treatment, relapses, pathol-
ogy, tumor markers, kidney function, lung function, etc. A questionnaire related to late effects 
has been conducted, which includes questions regarding social relationships, life situation, 
general health status, family background, diseases, symptoms, use of medication, marital status, 
psychosocial issues, fertility, and sexuality. TC survivors alive on October 2014 were invited 
to fill in this questionnaire including 160 validated questions. Collection of questionnaires is 
still ongoing. A biobank including blood/sputum samples for future genetic analyses has been 
established. Both samples related to DaTeCa and DMCG DaTeCa database are included. The 
prospective DMCG DaTeCa database includes variables regarding histology, stage, prognostic 
group, and treatment.
Conclusion: The DMCG DaTeCa database has existed since 2013 and is a young clinical 
database. It is necessary to extend the data collection in the prospective database in order to 
answer quality-related questions. Data from the retrospective database will be added to the 
prospective data. This will result in a large and very comprehensive database for future studies 
on TC patients.
Keywords: testis cancer, clinical indicators, database research, DaTeCa, DMCG DaTeCa 
database, hypogonadism
Aim of database
Testicular cancer (TC) is a rare disease, with ∼300 cases per year in Denmark. None-
theless, TC is the most common cancer in men aged 20–40 years. Today, it represents 
the most curable solid tumor with a 10-year survival of 90%–95%.1
With the high cure rate and young age at diagnosis, posttreatment morbidity plays 
a central role. Previous studies have shown an increased risk of secondary cancers, 
and conditions including heart disease, diabetes, hypogonadism, decreased fertility, 
and psychosocial problems.2 Data regarding risk factors for long-term side effects 
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of treatment are modest, and the precise risk of the various 
late side effects remains unresolved.
In Denmark, treatment of TC after orchiectomy has been 
increasingly centralized over the years, and is now performed 
only at three university hospitals. A common treatment and 
follow-up strategy has been developed across these centers 
(Table 1). National guidelines for treatment have been set by 
a multidisciplinary group. This group consists of represen-
tatives from all attending departments and from specialties 
relevant in the treatment of TC (www.ducg.dk). We have a 
large retrospective and a smaller prospective database, which 
will be merged in the coming years.
The overall aim of both databases is to improve the quality 
of care for patients with TC in Denmark. Several important 
issues related to treatment and survivorship of TC patients 
such as prognostic factors for relapse, treatment, follow-up, 
and late effects may be described through analyses of data 
from the clinical databases. So far, the focus has been on the 
following areas:
	 Analyses of quality indicators, benchmarking, quality 
audit, and feedback to departments.
	 Prognostic factors for relapse in stage I seminoma and 
nonseminoma patients.3,4
	 Rational follow-up of stage I patients in a surveillance 
program.3,4
	 Screening for contralateral carcinoma in situ testis.5
	 National treatment results for patients with metastatic 
disease including reanalysis of international risk factors 
published in 1997.6
	 Patients treated with more than one line of therapy for 
disseminated disease.7
	 Second primary cancer and cause of death.
	 Long-term morbidity in the form of cardiovascular 
disease, metabolic syndrome, neurotoxicity, nephro-
toxicity, pulmonary toxicity, hypogonadism, decreased 
fertility, and psychosocial problems.8,9
Study population
There are two TC databases in Denmark. Initially, the retro-
spective Danish Testicular Cancer (DaTeCa) database was 
constructed (Danish data protection agency J.nr. 2012-41-
0751). This is a research database comprising ∼6,000 Danish 
male patients with TC diagnosed from January 1, 1984 to 
December 31, 2007. Subsequently, the prospective Danish 
Multidisciplinary Cancer Group (DMCG) DaTeCa database 
was initiated in 2013 with prospective data collection of key 
clinical variables. The databases include cancers of both 
gonadal and extragonadal origin.
Patients in the retrospective DaTeCa database have been 
identified through the Danish National Patient Registry10 and 
hospital files. The diagnoses have been confirmed through 
manual review of pathology reports. The prospective DMCG 
DaTeCa database includes all incident TCs of both gonadal 
and extragonadal origin in Denmark recorded in the  Danish 
National Patient Registry and/or the Danish Pathology 
 Registry11 from 2013 onward. At present, ∼650 patients have 
been included in the database, with 300 new cases added 
every year. Up to now, the main focus has been on optimiz-
ing the validity of the algorithm for patient identification in 
the central registries, and validation of pathology data from 
three larger hospitals diagnosing and treating patients have 
revealed 100% coverage of histologically verified cancers. 
Further validation will ensure an even higher validity and 
completeness of data in the future.
Main variables
The retrospective DaTeCa database contains detailed informa-
tion with more than 300 variables related to histology, stage, 
treatment, relapses, pathology, tumor markers, kidney func-
tion, lung function, etc. Information about cause of death has 
been obtained from the Danish Registry of Causes of Death 
and cross-checked against journal files. Through linkage 
with national central registries, medical history after 5 years 
of standard follow-up program has been obtained, including 
vital status. A questionnaire related to late effects has been 
prepared, which includes issues on social relationships, life 
situation, general health status, family background, diseases, 
symptoms, use of medication, marital status, psychosocial 
issues, fertility, and sexuality. Patients have been asked to fill 
this questionnaire, and to deliver relevant blood/sputum tests 
Table 1 Testicular cancer – diagnosis and treatment
General staging:
Computed tomography scan and tumor markers (α-fetoprotein, human 
chorionic gonadotropin, lactate dehydrogenase)
Stage I:
Tumor in one or both testicles
Treatment
All patients followed on a surveillance program
Metastatic disease
Divided according to prognostic factors into a good, intermediate, and 
poor risk group
Treatment
Radiotherapy for stage iia and iib seminoma with lymph nodes ,3 cm. 
Three or four cycles of cisplatin, etoposide, and bleomycin for all other 
patients
Risk factors
Histology, tumor markers, metastases outside lung and lymph nodes, 
extragonadal tumors in mediastinum of nonseminoma origin
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Table 2 Clinical quality indicators in the prospective DaTeCa database and indicator fulfillment in 2013 and 2014
Indicator fulfillment %
Unknown 95% CI
Indicator Standard (%) % 2014 2013
Indicator 1a: CR after chemotherapy. Proportion of patients  
with good prognosis, with CR after chemotherapy
.95 21.3 95 (82–99) 100 (92–100)
Indicator 1b: CR after chemotherapy. Proportion of patients  
with intermediate prognosis, with CR after chemotherapy
.80 16.7 90 (55–100) 82 (48–98)
Indicator 1c: CR after chemotherapy. Proportion of patients  
with poor prognosis, with CR after chemotherapy
.60 71.4 100 (16–100) 60 (15–95)
Indicator 2: Secondary surgery. Proportion of patients with  
secondary surgery for residual tumor .1 cm and nonseminoma
.90 0.0 93 (68–100) 100 (82–100)
Indicator 3a: Relapse. Proportion of patients with relapse  
after stage i nonseminoma followed on a surveillance program
,30 0.0 16 (8–27)
Indicator 3b: Relapse. Number of patients with relapse after  
stage i seminoma followed on a surveillance program
,20 0.0 5 (2–10)
Indicator 4: Relapse. Proportion of patients with relapse after  
first-line treatment for disseminated disease
,15 0.0 6 (2–15)
Indicator 6: Pathology. Proportion of newly diagnosed patients  
with coding for pT stage
.95 95 (92–97) 88 (84–92)
Indicator 7: Pathology. Proportion of newly diagnosed patients  
with coding for vascular invasion: “present,” “not present,” or  
“evaluation not possible”
.95 69 (63–74) 56 (50–62)
Indicator 8: Pathology. Proportion of newly diagnosed patients  
with SNOMED coding for tumor diameter
.95 73 (68–78) 60 (54–66)
Abbreviations: DaTeCa database, Danish Testicular Cancer database; CI, confidence interval; CR, complete remission; pT, pathological tumor; SNOMED, Systematized 
Nomenclature of Medicine.
to a biobank for future genetic analyses. These data will be 
included in the retrospective database. In the longer term, the 
same data will be collected in the prospective database.
The prospective DMCG DaTeCa database includes 
variables regarding histology, stage, prognostic group, and 
treatment. These variables are obtained by data linkage to 
the Danish Pathology Registry (eg, histology and stage), 
the Danish National Patient Register (eg, medical history, 
surgical procedures, chemotherapy, and radiation therapy), 
and the Civil Registration System (data on vital status and 
migration). Additional key clinical variables are registered 
online in a web-based form by the treating clinicians at the 
oncological departments. These online registration forms 
are partly uniform for the five uro-oncological databases in 
Denmark. In 2013 and 2014, ∼98% of all newly diagnosed 
patients identified in the central registries have had an online 
registration form filled in.
Seven clinical quality indicators (four result indicators 
and three process indicators) are derived from the prospective 
database in order to monitor and improve the quality of care 
for patients with TC. These quality indicators include both 
indicators describing remission after treatment (indicator 
1a–c), surgery (indicator 2), occurrence of relapse (indicator 
3a–b, 4), prognosis, and the completeness of the pathological 
coding (indicator 5–7) (Table 2).
The relevant pathological codes used to identify prognosis 
and risk of relapse are important, and from 2013 to 2014, 
a significant improvement of coding practice was observed.12 
With continuous attention, also regarding coding of other 
clinical and paraclinical parameters, we found it possible to 
meet the expected quality standards.
Follow-up
Patients are followed by uniform national follow-up sched-
ules, usually for 5 years. After that, survival and possible 
relapse can be followed in national registries.
Examples of research
Patients with stage I TCs are followed for 5 years in a surveil-
lance program. It is demanded that follow-up programs are 
effective and relevant for the survival of the patient. We have 
used the retrospective database to obtain detailed informa-
tion about relapses including risk factors for relapse both in 
seminoma and nonseminoma patients.3,4 Furthermore, we 
have been able to suggest a timetable for follow-up.
The relapse rate after orchiectomy in stage I nonsemi-
noma was 30.6% after 5 years. Presence of vascular invasion 
together with embryonal carcinoma and rete testis invasion 
in the testicular primary identified a group of patients with 
a relapse risk of 50%. Without risk factors, the relapse 
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risk was 12%. With a median follow-up of 15 years in the 
 seminoma group, we found the relapse risk was 18.9%. Tumor 
size was an important risk factor for relapse. Either vascular 
invasion or invasion of epididymis was significant, if the 
other factor was excluded from analysis. For a patient with 
seminoma, and characterized by a tumor diameter of 8 cm and 
vascular invasion, the 5-year risk of recurrence was 40%.
Preventive treatment of recurrences of high-risk stage I 
patients with chemotherapy or radiation therapy is practiced 
at many centers worldwide. Based on our data, the risk factors 
underlying the selection of patients for treatment is incor-
rect. The newly defined risk factors identified through use 
of the DaTeCa database needs to be confirmed prospectively 
before deciding on adjuvant treatment in high-risk patients. 
As  Denmark is one of the few countries worldwide in which 
all stage I patients are followed with surveillance, the con-
firmation of risk factors will be performed on patients in the 
prospective DMCG DaTeCa database. Data completeness 
concerning histology in the prospective DMCG database 
is expected to be better compared with the retrospective 
database, and we aim to validate the risk factors mentioned 
above and possibly identify additional factors.
In 2015, the first annual report from the prospective 
DMCG DaTeCa database was published online at www. 
Sundhed.dk. The report contained detailed analyses on 
indicator fulfillment in 2013 and 2014 at the hospital level, 
regional level, and national level.
Administrative issues and funding
The retrospective DaTeCa database was created as a research 
database and analyses from this database have received 
support from various funding and already created several 
publications.3–5,7–9
The prospective DMCG DaTeCa database is under the 
auspices of the Danish Multidisciplinary Cancer Groups 
(DMCG.dk), which is an umbrella organization compris-
ing 24 national cancer groups and clinical databases in 
Denmark.13 The urological cancer groups and databases are 
further organized under the subgroup for Danish Urological 
Cancer Groups.14
The prospective DMCG DaTeCa database is publicly 
funded by the Danish Regions15 and under the administra-
tion of the Danish Clinical Registries (RKKP).16 Technical 
support and data management is provided by the Registry 
Support Centres of Clinical Quality and Health Informatics 
(West) (KCKS-Vest)17 and epidemiological and statistical 
support to the annual reports is provided by the Registry 
Support Centre of Epidemiology and Biostatistics (North) 
(KCEB-Nord).18 The Danish Clinical Registries (RKKP) is 
a nationwide initiative for monitoring and improving the 
quality of clinical care in Denmark.
Conclusion
The retrospective DaTeCa database is the most detailed data-
base concerning TC worldwide. The strength of the database 
is the complete and detailed information relating to treatment 
and that the treatment is consistent with today’s international 
standards, both in terms of stage I disease and chemotherapy 
for metastatic disease. We have focused on patients treated 
between 1984 and 2007 to ensure at least 5-year follow-up of 
all patients. It is the intention to use the prospective DMCG 
DaTeCa database to validate findings in the retrospective 
database and to expand the database to include a larger 
amount of data from public registries. The quality indicators 
will be used to improve quality of treatment. It is a challenge 
to identify and ensure the use of correct diagnosis codes 
so that all relevant patients are included in the database. 
Furthermore, data from the retrospective database will be 
added to the prospective data. This will result in a large and 
comprehensive database for future studies on TC patients. In 
the long term, the main variables in the prospective database 
should be expanded to cover results from relevant laboratory 
analyses, and results from specialized tests, that is, single 
nucleotide polymorphism analysis.
Data regarding the factors leading to long-term side 
effects of treatment are scarce. The introduction of new 
molecular testing methods allows us to use these tools to 
identify patients at high risk for therapy-related complications 
and thus the opportunity to develop risk-adapted screening 
and intervention strategies. The available database along with 
the biobank is optimal for this purpose.
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